Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
By M. Toft-Nielsen, M. Damholt, S. Madsbad, L. Hilsted, T. Hughes, Birgitte K. Michelsen, Jens J. Holst. Journal of Clinical Endocrinology and Metabolism, 2001
916 citations recorded by the source corpus.
Subfields: Endocrine and Autonomic Systems, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/4314fa1956921c5917ca5729053cb33014f7d95f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrine and Autonomic Systems
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. (2004, background): “(72) found near-normal fasting levels and meal responses, with no correlations between metabolic parameters and GIP responses.”
- Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. (2008, background): “GLP-1 levels are blunted (15), but the effect of administered GLP-1 on”
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “The deficiency of GLP-1 can be observed in individuals with IGT and worsens progressively with progression to type 2 diabetes (101).”
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “…patients with worse metabolic control, on multiple drugs and suffering from diabetes for longer times, have found impairments in GLP-1 secretion (Toft-Nielsen et al., 2001; Vilsbøll et al., 2001) and so chronic hyperglycemia and its metabolic consequences may be the cause of the slightly…”
- Incretin hormones: Their role in health and disease (2018, background): “Moreover, subjects with impaired glucose tolerance had an intermediate GLP-1 response.(141) Thus, it was hypothesized that there is a progressive loss of GLP-1 secretion with advancing stages of type 2 diabetes.”
- Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (2007, background): “The incretin pathway appears to be attenuated in type 2 diabetes, making the pathway a target for development of new pharmacologic agents.(7,8) In April 2005, the US Food and Drug Administration approved the first incretin mimetic, exenatide, a GLP-1 receptor analogue resistant to DPP4 degradation, ”